Tribio Anti-Human CD38 & BCMA & CD3 Bispecific Antibody (TBS10429)

Description

Description: Tribio CD38 & BCMA & CD3 Bispecific Antibody is an engineered multispecific antibody that targets CD38 and BCMA expressed on malignant plasma cells while simultaneously engaging CD3 on T lymphocytes. By bridging T cells with tumor cells, this antibody promotes targeted T cell activation, cytokine release, and potent cytotoxic responses against CD38/BCMA-positive cancer cells. It is commonly used in immuno-oncology research for evaluating T cell redirection, immune-mediated tumor clearance, and therapeutic strategies for hematologic cancers, particularly multiple myeloma and related plasma cell disorders.

Applications: ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Species reactivity: Human

Host species: Human

Target: Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2′-phospho-ADP-ribosyl cyclase/2′-phospho-cyclic-ADP-ribose transferase, T10, 2′-phospho-cyclic-ADP-ribose transferase, CD38, ADPRC 1, ADP-ribosyl cyclase 1, 2′-phospho-ADP-ribosyl cyclase, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain, Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM

Isotype: IgG1-kappa-IgG1-Fab (Trispecific Antibody)

Accession/UniProt: P28907 & Q02223 & P07766

Concentration: 3 mg/ml

Purity: >95%

Formulation: Liquid

Storage buffer: 0.01M PBS, pH 7.4

Purification: Protein A/G purified from cell culture supernatant.

Storage: Avoid repeated freeze-thaw cycles. -20°C for 12 months; -80°C for long-term storage.

Research use only.

Additional information